Grantham Mayo Van Otterloo & Co. LLC Buys Shares of 18,789 Sanofi (NASDAQ:SNY)

Grantham Mayo Van Otterloo & Co. LLC acquired a new stake in Sanofi (NASDAQ:SNY - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,789 shares of the company's stock, valued at approximately $906,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Abel Hall LLC increased its holdings in shares of Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after purchasing an additional 194 shares during the period. Providence Capital Advisors LLC raised its position in shares of Sanofi by 0.4% during the 4th quarter. Providence Capital Advisors LLC now owns 55,001 shares of the company's stock worth $2,653,000 after buying an additional 201 shares in the last quarter. Keudell Morrison Wealth Management boosted its holdings in shares of Sanofi by 1.7% in the fourth quarter. Keudell Morrison Wealth Management now owns 12,928 shares of the company's stock valued at $624,000 after acquiring an additional 217 shares in the last quarter. Bailard Inc. increased its stake in shares of Sanofi by 1.4% during the fourth quarter. Bailard Inc. now owns 16,359 shares of the company's stock valued at $789,000 after acquiring an additional 220 shares during the period. Finally, Old Port Advisors lifted its position in Sanofi by 0.6% in the fourth quarter. Old Port Advisors now owns 36,704 shares of the company's stock worth $1,770,000 after purchasing an additional 232 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SNY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. The Goldman Sachs Group initiated coverage on Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective for the company. Finally, Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $62.50.

Sanofi Trading Up 1.2 %

NASDAQ SNY traded up $0.63 on Monday, hitting $52.13. 264,724 shares of the stock were exchanged, compared to its average volume of 2,318,938. The company's 50-day moving average price is $54.97 and its two-hundred day moving average price is $52.35. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12. The company has a market capitalization of $131.69 billion, a price-to-earnings ratio of 20.94, a P/E/G ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Research analysts predict that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.